Vistara gets Rs 465-crore fund infusion from Tata Sons, Singapore Airlines

Vistara plans to expand its operation significantly by 2023, which is the primary reason behind the carrier’s aggressive capital infusion moves. The airline has already started flying to London and Tokyo this year and has filed for permission in the US to fly from September.

Yaruqhullah Khan

May 13, 2021 / 19:01 IST

Tata Sons Ltd, the holding company of Tata group, and Singapore Airlines Ltd - the two promoters of Vistara - have infused an additional Rs 465 crore into the airline, data accessed by the business intelligence platform, Tofler showed.

The airline’s board approved the allotment of 46.5 crore shares of Rs 10 each to the two promoters, data from Tofler, which was seen by Moneycontrol, showed.

The airline's promoters had slowed down on fund infusion in 2020 as international operations were shut for a large part of the year due to restrictions imposed by the governments to contain the spread of deadly coronavirus. However, they are now looking at equity injection to expand its international operations.

Vistara plans to expand its operation significantly by 2023, which is the primary reason behind the carrier’s aggressive capital infusion moves. The airline has already started flying to London and Tokyo this year and has filed for permission in the US to fly from September.

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show